Image-guided percutaneous ablation is currently accepted as the best therapeutic choice for non-surgical patients with early-stage HCC.
Image-guided Ablation
Image-guided percutaneous ablation is currently accepted as the best therapeutic choice for non-surgical patients with early-stage HCC. 3, 4 Over the past two decades, several methods for chemical ablation or thermal tumour destruction through localised heating or freezing have been developed and clinically tested. 6, 7 Ethanol Injection
The seminal technique used for local ablation of HCC is percutaneous ethanol injection (PEI). Ethanol induces coagulation necrosis of the lesion as a result of cellular dehydration, protein denaturation and chemical occlusion of small tumour vessels. PEI is a well-established technique for the treatment of nodular-type HCC. HCC nodules have a soft consistency and are surrounded by a firm cirrhotic liver.
in lesions smaller than 3cm and 43% in lesions exceeding 3cm. 10, 11 The injected ethanol does not always accomplish complete tumour necrosis because of its non-homogeneous distribution within the lesionespecially in the presence of intratumoural septa -and the limited effect on extracapsular cancerous spread. The recent introduction of dedicated multipronged PEI needles (QuadraFuse, Rex Medical) has been shown to overcome some of these limitations. 12 
Radiofrequency Ablation
Radiofrequency (RF) ablation has been the most widely assessed alternative to PEI for local ablation of HCC. Several electrode types are available for clinical RF ablation, including internally cooled electrodes and multitined expandable electrodes with or without perfusion. 6 The thermal damage caused by heating is dependent on both the tissue temperature achieved and the duration of heating. Microwave irradiation creates an ablation area around the needle in a column or round shape, depending on the type of needle used and the generating power. Only one RCT compared the effectiveness of microwave ablation with that of RF ablation. 23 Although no statistically significant differences were observed with respect to the efficacy of the two procedures, a tendency favouring RF ablation was recognised with respect to local recurrences and complication rates. However, it has to be pointed out that microwave ablation technology has evolved significantly since the publication of this study. Liver Cancer
Transcatheter Treatment
Transarterial Chemo-embolisation HCC exhibits intense neo-angiogenic activity during its progression. The rationale for TACE is that the intra-arterial infusion of a drug such as doxorubicin or cisplatin with a viscous emulsion (e.g. lipiodol), followed by embolisation of the blood vessel with gelatine sponge particles or other embolic agents, will result in a strong cytotoxic effect combined with ischaemia. Cumulative meta-analysis of all published randomised trials indicates that survival of patients with HCC not suitable for radical therapies treated with TACE is improved compared with best supportive care. 26 However, the outcome of TACE depends on careful patient selection. In a randomised trial that recruited patients with compensated cirrhosis (70% in Child-Pugh A), absence of cancer-related symptoms (81% with ECOG performance status of 0) and large or multinodular HCC with neither vascular invasion nor extrahepatic spread, two-year survival reached 63% compared with 27% in the untreated control arm (p=0.009). 27 In another randomised study, the use of broader enrolment criteria with inclusion of patients with symptoms or limited portal vein invasion resulted in a two-year survival of 31%. This figure was still superior to that of the untreated control group (two-year survival 11%); however, no survival benefit was identified in the subgroup analysis restricted to patients presenting with portal vein invasion. 28 As a result of these investigations, TACE has been established The ideal TACE scheme should allow for the maximum and sustained concentration of the chemotherapeutic drug within the tumour with minimal systemic exposure combined with tumoral vessel obstruction.
The recent introduction of an embolic microsphere composed of a polyvinyl l alcohol macromer (DC Bead, Biocompatibles), which has the ability to actively sequester doxorubicin hydrochloride from solution and release it in a controlled and sustained fashion, has been shown to substantially diminish the amount of chemotherapy that reaches the systemic circulation, thus significantly increasing the antitumoral efficacy and reducing drug-related adverse events with respect to conventional regimens. 29, 30 In a phase II randomised trial, DC Bead-TACE with doxorubicin showed a higher rate of objective response and disease control compared with conventional TACE with doxorubicin, lipiodol and gelatin sponge particles, although the observed difference was not statistically significant. 30 There was also a marked reduction in serious liver toxicity in patients treated with DC Bead-TACE, and the rate of doxorubicin-related side effects was significantly lower in the DC Bead-TACE group compared with the conventional TACE group (12 versus 26%).
Transarterial Radio-embolisation
The use of external beam radiation therapy in HCC treatment has been limited by the low radiation tolerance of the non-tumoral cirrhotic liver.
Internal radiation therapy, also called radio-embolisation, consists of Following curative treatment, patients (target enrolment 1,100) are randomised to receive either sorafenib 400mg twice daily or placebo, with the primary aim to investigate the differences in recurrence-free survival.
Tumour recurrence following TACE is characterised by increased vascular endothelial growth factor (VEGF) production and subsequent angiogenesis. In one study, changes in the biological behaviour of residual viable HCC tissue after TACE were evaluated. Tumour specimens from 42 patients treated by surgery alone (control group) and 21 patients who received TACE one to two times prior to surgical resection were analysed. The number of VEGF-positive cells in the TACE group was significantly higher than that in the control group, suggesting that TACE increases VEGF expression in the residual surviving cancerous tissue. 34 Other experimental investigations suggest that TACE induces expression of other pro-angiogenic
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factors, such as hypoxia-inducible factor-1alpha (HIF-1alpha). 35 In a Based on these findings, combination of sorafenib with TACE would appear a rational approach. A phase II randomised trial, the SPACE study, is ongoing, comparing DC Bead-TACE plus placebo versus DC Bead-TACE plus sorafenib. In this study, TTP is the primary end-point.
However, given that the period of time during which patients, even when experiencing progression, remain eligible for TACE is clinically relevant, a novel end-point, 'time to untreatable progression', is also being investigated in the SPACE trial. This will be defined as the time from the date of randomisation to the time that the disease progresses from an intermediate to an advanced stage as defined by specific events. OS will be evaluated as a secondary end-point in this study. In fact, this evaluation will take into account subsequent lines of treatment after disease progression that may influence survival, such as sorafenib.
The above-mentioned ongoing trials are the first significant studies in which an interventional loco-regional treatment is being evaluated in combination with a systemically active molecular-targeted drug in HCC. The outcomes of these combination studies are eagerly awaited, 
